Anavex Life Sciences Corp. (AVXL)

1.11 -0.15 (-11.90%) USD  |  NASDAQ  |  Nov 05, 16:00
1.105 0.00 (0.00%) After-Hours: 20:00
More

Anavex Life Sciences SG&A Expense (TTM) : 5.935M for June 30, 2026

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 5.935M
March 31, 2026 12.47M
December 31, 2025 12.80M
September 30, 2025 13.82M
June 30, 2025 13.05M
March 31, 2025 11.41M
December 31, 2024 11.58M
September 30, 2024 11.04M
June 30, 2024 10.85M
March 31, 2024 11.24M
December 31, 2023 11.33M
September 30, 2023 12.04M
June 30, 2023 13.35M
March 31, 2023 13.29M
December 31, 2022 13.32M
September 30, 2022 13.07M
June 30, 2022 12.05M
March 31, 2022 11.30M
December 31, 2021 10.61M
September 30, 2021 9.018M
June 30, 2021 7.542M
March 31, 2021 6.489M
December 31, 2020 5.975M
September 30, 2020 5.857M
June 30, 2020 6.089M
Date Value
March 31, 2020 6.096M
December 31, 2019 6.437M
September 30, 2019 6.847M
June 30, 2019 6.693M
March 31, 2019 6.924M
December 31, 2018 6.353M
September 30, 2018 5.989M
June 30, 2018 5.869M
March 31, 2018 5.653M
December 31, 2017 5.280M
September 30, 2017 5.008M
June 30, 2017 5.891M
March 31, 2017 5.862M
December 31, 2016 5.599M
September 30, 2016 8.335M
June 30, 2016 9.311M
March 31, 2016 8.648M
December 31, 2015 8.247M
September 30, 2015 4.837M
June 30, 2015 1.912M
March 31, 2015 1.932M
December 31, 2014 2.384M
September 30, 2014 2.171M
June 30, 2014 2.180M
March 31, 2014 1.532M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Vaxcyte, Inc. 100.22M
Foghorn Therapeutics, Inc. 26.38M
Connect Biopharma Holdings Ltd. 13.09M
Caribou Biosciences, Inc. 33.74M
Arrowhead Pharmaceuticals, Inc. 172.57M